Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings.
cardiac arrhythmia
clinical trials
electrocardiogram
obesity
overweight
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
06
10
2022
accepted:
07
12
2022
medline:
12
4
2023
pubmed:
17
12
2022
entrez:
16
12
2022
Statut:
ppublish
Résumé
Although estimates of the prevalence of cardiac arrhythmias in healthy volunteers exist, there is a lack of baseline data in other specific populations, such as people living with overweight and obesity, who are increasingly involved in clinical trials. This study investigated the baseline prevalence of arrhythmias in participants with overweight or obesity in 2 phase 1 trials of weight management medications (NCT03661879, NCT03308721). Participants aged 18-55 years, without a history of cardiovascular disease, and with body mass index (BMI) of 25.0-39.9 kg/m
Banques de données
ClinicalTrials.gov
['NCT03661879', 'NCT03308721']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
539-543Informations de copyright
© 2022, The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
U.S. Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. https://www.fda.gov/media/71372/download. Published October 2005. Accessed December 20, 2021.
Kothari S, Karnad DR, Panicker GK, Turner JR. Cardiac safety investigations 10 years after ICH guidance E14: evolving industry and regulatory viewpoints on evaluation of proarrhythmic risk during new drug development. J Clin Stud. 2015;7:22-30.
European Medicines Agency. ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (R3) - questions and answers. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e14-clinical-evaluation-qt/qtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-r3-questions-answers-step_en.pdf. Published January 25, 2016. Accessed December 20, 2021.
Hingorani P, Karnad DR, Rohekar P, Kerkar V, Lokhandwala YY, Kothari S. Arrhythmias seen in baseline 24-hour Holter ECG recordings in healthy normal volunteers during phase 1 clinical trials. J Clin Pharmacol. 2016;56(7):885-893.
Hingorani P, Karnad DR, Natekar M, Kothari S, Narula D. Baseline and new-onset morphologic ECG abnormalities in healthy volunteers in phase I studies receiving placebo: changes over a 6-week follow-up period. J Clin Pharmacol. 2014;54(7):776-784.
Min SS, Turner JR, Nada A, et al. Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development. Am Heart J. 2010;159(5):716-729.
Stinson JC, Pears JS, Williams AJ, Campbell RW. Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmacol. 1995;39(6):651-656.
Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs. 2010;10(5):321-334.
Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Saf. 2010;33(7):605-613.
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Under-reporting of adverse effects of tesofensine. Lancet. 2013;382(9887):127.
Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-588.
Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107-1117.
Vedel-Larsen E, Iepsen EW, Lundgren J, et al. Major rapid weight loss induces changes in cardiac repolarization. J Electrocardiol. 2016;49(3):467-472.
Ilson BE. Cardiovascular monitoring in normal healthy adults: a literature review and recommendations for the reporting of disturbances of cardiac rhythm. Am J Ther. 1995;2(11):893-899.
Bjerregaard P. Premature beats in healthy subjects 40-79 years of age. Eur Heart J. 1982;3(6):493-503.
von Rotz M, Aeschbacher S, Bossard M, et al. Risk factors for premature ventricular contractions in young and healthy adults. Heart. 2017;103(9):702-707.
Fraley MA, Birchem JA, Senkottaiyan N, Alpert MA. Obesity and the electrocardiogram. Obes Rev. 2005;6(4):275-281.
Arslan E, Yiğiner O, Yavaşoğlu I, Ozçelik F, Kardeşoğlu E, Nalbant S. Effect of uncomplicated obesity on QT interval in young men. Pol Arch Med Wewn. 2010;120(6):209-213.
Pathak RK, Mahajan R, Lau DH, Sanders P. The implications of obesity for cardiac arrhythmia mechanisms and management. Can J Cardiol. 2015;31(2):203-210.
Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Ketikoglou DG. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015;66(5):361-369.